In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LG Life Sciences-Green Cross Tie-up Might Not Trigger Matching Alliances By Other Korean Drug Makers

This article was originally published in PharmAsia News

Executive Summary

SEOUL - A recent deal covering cooperation in domestic and global sales between South Korea's second largest pharmaceutical company, Green Cross, and 10-ranked LG Life Sciences has not yet triggered any similar tie-ups by other major drug players

You may also be interested in...



Korea Biosimilar Play LG Life Sciences Names New CEO Amid Unfriendly Business Conditions

SEOUL - LG Life Sciences has reshuffled its top management and named Jung Il-Jae as new CEO and President. Kim In-Chull had served as president of LG Life Sciences since 2006, and took the lead in aggressively moving the company into the biosimilar space. The company said only that Kim will now serve as an advisor to the company

Korea Biosimilar Play LG Life Sciences Names New CEO Amid Unfriendly Business Conditions

SEOUL - LG Life Sciences has reshuffled its top management and named Jung Il-Jae as new CEO and President. Kim In-Chull had served as president of LG Life Sciences since 2006, and took the lead in aggressively moving the company into the biosimilar space. The company said only that Kim will now serve as an advisor to the company

Korea's LG Life Sciences Teams with Macrogen to Pool Genetics Databases for Personalized Medicines and Theranostics

SEOUL - South Korea's LG Life Sciences hopes to bring new life to its stalled oncology program by inking a memorandum of understanding with genomic services provider Macrogen to work together for the development and commercialization of personalized medicine using patients' genetic information

Related Content

UsernamePublicRestriction

Register

SC074738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel